Current Research Efforts
AGXV Series - Cholesterol-lowering immunotherapies
Finally, a real solution to high cholesterol
CURRENT STAGE: Lab testing of AGXV1 with our research partner, La Cite collegiale,
AGXV2 & AGXV3 in conceptual development.
Our primary focus is our set of immunotherapies designed to permanently enhance cholesterol metabolism through an immune system-mediated removal of inhibitory factors. Our proprietary multitope platform allows for a more targeted immune response to our targets, promising greater LDL and VLDL clearance than competitors. Our AGXV Series is designed to be modular, for synergistic rewiring of cholesterol metabolism.
AGXV1 preclinical studies underway.